INGRAM DOUGLAS S 4
4 · Relay Therapeutics, Inc. · Filed Jun 10, 2026
Research Summary
AI-generated summary of this filing
Relay Therapeutics Director Douglas Ingram Receives Option Award
What Happened
Douglas S. Ingram, a director of Relay Therapeutics, was granted a derivative award on June 9, 2026 covering 32,947 shares of the company's common stock. The award was reported at $0.00 (grant of an option/award rather than an open-market purchase or sale). The filing does not show any exercise or sale of shares — this is a grant of rights to acquire shares subject to vesting.
Key Details
- Transaction date and type: June 9, 2026 — Grant/Award (Form 4 code A).
- Quantity and price: 32,947 shares; reported acquisition price $0.00 (derivative award).
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Notable footnote: The option vests in full on the earlier of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders.
- Filing timeliness: Report lists Period of Report 2026-06-09 and was filed 2026-06-10 — appears to be timely.
Context
This was a stock-based compensation award (an option/derivative grant), not a purchase or sale. Such awards are common for board members and do not by themselves indicate insider buying or selling sentiment. The options have vesting conditions; there is no evidence here of immediate exercise or sale.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-06-09+32,947→ 32,947 totalExercise: $14.09Exp: 2036-06-08→ Common Stock (32,947 underlying)
Footnotes (1)
- [F1]This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.